Morbidity Measures: Incidence, Prevalence, and Case Fatality Rates

When epidemiologists track a disease, they don’t just count sick people. They ask sharper questions: how fast are new cases appearing, how many people are living with the condition right now, and how deadly is it once you’ve got it? These three questions are answered by three core measures of morbidity: incidence rate, prevalence rate, and case fatality rate. Together, they form the basic vocabulary of disease surveillance, and they shape almost every public health decision, from a state’s TB elimination plan to a hospital’s pandemic response.

What morbidity actually means
Incidence rate: the speed of new cases
Why incidence matters for outbreak control
Prevalence rate: the total picture at a snapshot
Point prevalence and period prevalence
How incidence and prevalence interact
Case fatality rate: measuring how deadly a disease is
CFR during the COVID-19 pandemic
The difference between CFR and infection fatality rate
Putting the three measures together
Common pitfalls in interpreting morbidity measures

What morbidity actually means

Before getting into the formulas, it helps to be clear about what is being measured. Morbidity refers to any departure from a state of complete health, including disease, injury, or disability. While mortality is about death, morbidity is about being ill or unwell while still alive. Public health systems track morbidity to understand the burden of disease on a population, plan healthcare services, and evaluate whether interventions are working.

Three measures dominate the conversation. Incidence captures how quickly new cases are appearing. Prevalence captures the total stock of cases at a given moment. Case fatality rate captures how lethal a confirmed case turns out to be. Each answers a different question, and confusing them is one of the most common mistakes in reading health statistics.

Incidence rate: the speed of new cases

The incidence rate measures how many new cases of a disease appear in a defined population over a specific period of time. The standard formula is:

Incidence Rate = (Number of new cases during a time period ÷ Population at risk during that period) × 1,000 (or 1,00,000)

The multiplier – typically 1,000 or 1,00,000 – is just a way of expressing the rate as a clean number that can be compared across populations of different sizes. For a rare cerebrovascular condition, researchers may even use 1,000,000 as the multiplier, since cases are so few. For instance, a population-based study reported an overall incidence of cerebral vein thrombosis of 13.2 per 1,000,000 per year.

The key word in the formula is new. Anyone who already had the disease before the period began does not count in the numerator. That is what makes incidence a measure of risk and of disease spread. If incidence is rising, something is going wrong – either the disease is being transmitted faster, more people are being exposed to a risk factor, or surveillance is catching cases that were previously missed.

Why incidence matters for outbreak control

Tuberculosis is a useful example for an Indian audience because the country carries a quarter of the global burden. According to the Ministry of Health and Family Welfare, India’s TB incidence reduced from 237 per lakh in 2015 to 187 per lakh in 2024, a 21 per cent drop that outpaced the global decline. That single number tells policymakers something important: the rate at which new TB cases are emerging is slowing down, suggesting that prevention, screening, and treatment efforts under the National TB Elimination Programme are gaining ground.

Incidence is also sensitive to local conditions. Within India, Delhi reports TB incidence of around 499 per 100,000 while Kerala reports about 76 per 100,000. Same disease, same country, but vastly different rates of new infection – reflecting differences in population density, nutrition, healthcare access, and reporting quality.

Prevalence rate: the total picture at a snapshot

Where incidence captures the flow of new cases, prevalence captures the stock – the total number of existing cases, old and new combined, at a given point in time or over a defined interval. The formula is:

Prevalence Rate = (Total number of existing cases ÷ Total population) × 1,000 (or 1,00,000)

Prevalence is usually expressed as a proportion or percentage rather than as a “rate” in the strict mathematical sense, but the term “prevalence rate” is widely used in textbooks and public health reports.

Point prevalence and period prevalence

There are two main flavours. Point prevalence measures the proportion of people with the disease on a specific date – useful for a one-day household survey. Period prevalence measures the proportion of people who had the disease at any time during a longer interval, such as a year. Period prevalence includes both new and pre-existing cases that occurred during the time period, which makes it a broader figure than point prevalence.

Prevalence is particularly suited to chronic conditions such as diabetes, hypertension, or arthritis, where people live with the disease for years. For acute conditions like seasonal influenza, where most patients recover within days, prevalence at any given moment may be low even when incidence over a season is high.

How incidence and prevalence interact

The two measures are mathematically linked. In a simple stable population, prevalence is roughly equal to incidence multiplied by the average duration of the disease. This relationship has a counterintuitive consequence: a deadly disease can show low prevalence even when incidence is high, because patients die quickly and are no longer counted among existing cases. As one public health analysis explains, a high fatality rate reduces prevalence because, when people die, they are no longer counted among the existing cases. Conversely, a chronic disease with a long survival time can show high prevalence even when very few new cases occur each year.

This is why looking at prevalence alone can mislead. A drop in prevalence might be good news (people are being cured) or terrible news (people are dying faster). You need incidence and case fatality figures alongside it.

Case fatality rate: measuring how deadly a disease is

The case fatality rate (CFR) measures the proportion of people diagnosed with a disease who die from it within a specified period. The formula is:

CFR (%) = (Number of deaths from a disease ÷ Number of diagnosed cases of that disease) × 100

CFR is expressed as a percentage and answers a single, blunt question: if you get this disease, what is the chance it will kill you? Ebola virus disease, with past outbreaks reaching CFRs of up to 90 per cent, is among the deadliest. The common cold has a CFR effectively at zero. Most diseases sit somewhere in between.

CFR during the COVID-19 pandemic

The COVID-19 pandemic made CFR a household concept. Early in the outbreak, India’s CFR was estimated at over 3 per cent. As testing expanded and milder cases were detected, the denominator grew and the CFR fell. By September 2020, the WHO Global TB context aside, India’s calculated case fatality rate had reduced to around 1.59 per cent compared with 3.38 per cent in April. By 2024, the global CFR for TB was reported at 11.5 per cent, while COVID-19’s CFR has continued to shift with each variant and wave.

Two things make CFR tricky to interpret. First, it depends heavily on how many cases are being detected. A country with poor testing will diagnose only the sickest patients, inflating the CFR. A country with strong surveillance will catch mild cases, driving the CFR down. Second, CFR depends on healthcare quality – the same disease can have a far higher CFR in a region with overwhelmed hospitals than in one with well-resourced ICUs.

The difference between CFR and infection fatality rate

Epidemiologists also use the Infection Fatality Rate (IFR), which divides deaths by all infected people, including those who were never diagnosed. IFR is almost always lower than CFR, but it is much harder to estimate because you need to know the true number of infections, often only available through serosurveys. For India, one analysis estimated the COVID-19 IFR at between 0.58 and 1.16 per 100 after adjusting for routine death surveillance gaps, considerably higher than the officially reported CFR at the time. The same study noted that India’s routine death surveillance covers only about 18.1 per cent of deaths, which complicates fatality estimates.

Putting the three measures together

Each measure illuminates a different facet of the same disease. Consider how a health department might read a TB report:

Incidence tells them whether transmission is being controlled. If new cases per lakh are falling, the prevention pipeline is working.

Prevalence tells them how large the patient pool is right now – how many people need treatment, drugs, and follow-up care. A national prevalence survey conducted between 2019 and 2021 estimated a 31 per cent tuberculosis infection burden among individuals above 15 years of age, which is a vastly different number from incidence and reflects the deep reservoir of latent infection.

Case fatality rate tells them how dangerous the disease remains for those already diagnosed, and indirectly how well treatment is working. Falling CFR usually means better drugs, faster diagnosis, or improved hospital care.

Public health policy almost always needs all three. A programme that reduces incidence without improving CFR has cut transmission but left existing patients vulnerable. A programme that reduces CFR without touching incidence is saving lives but failing to prevent new infections. A useful surveillance system tracks them in parallel.

Common pitfalls in interpreting morbidity measures

A few traps are worth flagging. Confusing prevalence with incidence is the most common – newspapers often report total cases of a disease as if that captures the rate of spread, when in fact it conflates new and old cases. Comparing CFRs across countries without adjusting for testing coverage or age structure can be misleading; an older population will almost always show a higher CFR for diseases like COVID-19, regardless of healthcare quality. And calculating an incidence rate without specifying the population at risk and the time period makes the number meaningless.

Good epidemiological reporting always specifies the numerator, the denominator, the multiplier, and the time frame. When you see “187 per lakh population in 2024” for TB incidence, every part of that phrase is doing work.

What do you think? If a state reports falling TB prevalence but rising case fatality rate, what would you suspect is happening on the ground? And in a future outbreak of a new infectious disease, which of the three measures would you watch most closely in the first month, and why?

References

PDF 📄

Morbidity Measures: Incidence, Prevalence, and Case Fatality Rates

Table of Contents

What morbidity actually means 🔗

Incidence rate: the speed of new cases 🔗

Why incidence matters for outbreak control 🔗

Prevalence rate: the total picture at a snapshot 🔗

Point prevalence and period prevalence 🔗

How incidence and prevalence interact 🔗

Case fatality rate: measuring how deadly a disease is 🔗

CFR during the COVID-19 pandemic 🔗

The difference between CFR and infection fatality rate 🔗

Putting the three measures together 🔗

Common pitfalls in interpreting morbidity measures 🔗